Compare DCBO & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCBO | KMDA |
|---|---|---|
| Founded | 2016 | 1990 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 489.9M | 458.6M |
| IPO Year | 2020 | 2013 |
| Metric | DCBO | KMDA |
|---|---|---|
| Price | $19.06 | $8.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $32.00 | $13.00 |
| AVG Volume (30 Days) | ★ 270.9K | 67.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.18% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.54 | $14.79 |
| Revenue Next Year | $11.82 | $11.38 |
| P/E Ratio | ★ $22.04 | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.07 | $5.54 |
| 52 Week High | $33.69 | $9.35 |
| Indicator | DCBO | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 54.98 | 56.71 |
| Support Level | $18.11 | $6.69 |
| Resistance Level | $20.15 | $9.35 |
| Average True Range (ATR) | 0.97 | 0.26 |
| MACD | 0.26 | -0.01 |
| Stochastic Oscillator | 86.72 | 63.16 |
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.